Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Prostate Cancer

Prostate Cancer

18 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Prostate Cancer

669 trials tracked for Prostate Cancer: 125 in phase 3 or 4 and 47 with published results. The most-cited published study has 1650 citations.

669Trials tracked
125Phase 3 & 4
0Recruiting
47With published results
Phase distribution
Phase 4 15 Phase 3 110 Phase 2 350 Phase 1 43 Other / NA 151
  1. Phase 3 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Completed · 1,650 cited
  2. Phase 3 Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence Completed · 784 cited
  3. Phase 3 Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer Completed · 700 cited
  4. Phase 3 Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy Completed · 658 cited
  5. Phase 3 Radiation Therapy in Treating Patients With Stage II Prostate Cancer Completed · 628 cited
  6. Phase 3 SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer Completed · 568 cited
Show 44 more trials
  1. Phase 3 A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer Completed · 431 cited
  2. Phase 3 Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms Completed · 395 cited
  3. Phase 3 Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Completed · 356 cited
  4. Phase 3 Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients Completed · 336 cited
  5. Phase 3 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Completed · 333 cited
  6. Phase 3 Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Completed · 288 cited
  7. Phase 3 Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 Completed · 247 cited
  8. Phase 3 Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Completed · 230 cited
  9. Phase 3 Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer. Completed · 230 cited
  10. Phase 3 FACBC Outcomes for Post Prostatectomy Completed · 182 cited
  11. Phase 4 Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients Completed · 171 cited
  12. Phase 3 Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Completed · 138 cited
  13. Phase 3 Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer Completed · 134 cited
  14. Phase 3 Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer Completed · 132 cited
  15. Phase 3 Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) Completed · 131 cited
  16. Phase 3 Radiation Therapy in Treating Patients With Stage II Prostate Cancer Completed · 118 cited
  17. Phase 3 S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer Completed · 111 cited
  18. Phase 3 Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer Completed · 107 cited
  19. Phase 3 Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer. Completed · 90 cited
  20. Phase 3 Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy Completed · 62 cited
  21. Phase 3 Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) Completed · 49 cited
  22. Phase 3 Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Completed · 41 cited
  23. Phase 3 Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer Completed · 38 cited
  24. Phase 3 S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Completed · 37 cited
  25. Phase 3 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment Completed · 31 cited
  26. Phase 3 Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma Completed · 29 cited
  27. Phase 3 A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) Completed · 29 cited
  28. Phase 3 A Study of Degarelix in Patients With Prostate Cancer Completed · 25 cited
  29. Phase 3 Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer Completed · 25 cited
  30. Phase 3 Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Completed · 20 cited
  31. Phase 3 Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer Completed · 20 cited
  32. Phase 3 PROvenge Treatment and Early Cancer Treatment Completed · 18 cited
  33. Phase 3 Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer Completed · 17 cited
  34. Phase 4 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer Completed · 13 cited
  35. Phase 4 A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients Completed · 9 cited
  36. Phase 3 Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence Completed · 6 cited
  37. Phase 3 Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Completed · 2 cited
  38. Phase 3 A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Completed · 2 cited
  39. Phase 3 Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance Completed
  40. Phase 3 Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer Completed
  41. Phase 3 Study of Diagnostic Performance of [18F]CTT1057 in BCR Completed
  42. Phase 4 Global Performance Evaluation of the AMS CONTINUUM™ Device Completed
  43. Phase 4 Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery Completed
  44. Phase 4 A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients. Completed

Showing the 50 most-cited and recently-updated of 669 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Liquid biopsy shows high sequencing success in high-risk localized prostate cancer feasibility study
Urology Phase II
Liquid biopsy shows high sequencing success in high-risk localized prostate cancer feasibility study Blood Tests Replace Biopsies for Prostate Cancer
A phase 2 neoadjuvant trial in 22 patients with high-risk localized prostate cancer found liquid-based genomic profiling achieved 100% seque…
A simple blood draw now replaces painful prostate biopsies, capturing the same genetic details doctors need to pick the best treatment.
Frontiers Apr 10, 2026
Targeted plus perilesional biopsy noninferior to combined biopsy for prostate cancer detection
Urology RCT
Targeted plus perilesional biopsy noninferior to combined biopsy for prostate cancer detection Could a simpler prostate biopsy find dangerous cancers just as well?
A single-center RCT in 380 biopsy-naïve patients with a single unilateral suspicious MRI lesion found targeted plus perilesional biopsy (TPL…
A simpler prostate biopsy found dangerous cancers just as well as the standard method while causing less pain and bleeding for men with susp…
Apr 6, 2026
Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial
Oncology RCT
Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial Can a targeted radiation drug delay prostate cancer progression without hormone therapy?
A phase 2 randomized controlled trial of 58 men with biochemically recurrent oligometastatic hormone-sensitive prostate cancer found Lu-PSMA…
A targeted radiation drug delayed prostate cancer progression by 20 months in early-stage patients without requiring hormone therapy first.
Apr 6, 2026
Prior HoLEP association with longer operative time and catheter duration in subsequent RARP
Urology Meta-analysis
Prior HoLEP association with longer operative time and catheter duration in subsequent RARP Does prior prostate surgery make your next operation harder or riskier?
This systematic review and meta-analysis of three retrospective studies compared men undergoing robot-assisted radical prostatectomy (RARP) …
Prior prostate surgery makes the next operation take longer and requires more rebuilding, but cancer removal and recovery remain just as eff…
Apr 6, 2026
Phase 2 trial of muscadine grape extract added to ADT for recurrent prostate cancer fatigue
Urology Phase II
Phase 2 trial of muscadine grape extract added to ADT for recurrent prostate cancer fatigue Muscadine grape extract studied for fatigue in men with recurrent prostate cancer
A Phase 2 randomized controlled trial enrolled 106 men with recurrent prostate cancer on androgen deprivation therapy to test muscadine grap…
Men with recurrent prostate cancer taking hormone therapy may feel less extreme fatigue when adding a natural muscadine grape extract supple…
CT.gov Apr 4, 2026
Qualitative study finds knowledge gaps and insurance concerns about prostate cancer genetic testing
Genetics & Precision Medicine Phase II
Qualitative study finds knowledge gaps and insurance concerns about prostate cancer genetic testing What stops men from getting genetic testing for prostate cancer?
A qualitative and survey study of 20 men with prostate cancer, plus patients, carers, and healthcare providers, found generally low knowledg…
Fear of insurance discrimination and low knowledge about genetic testing are stopping many men from getting prostate cancer tests that could…
medRxiv Apr 3, 2026

Questions about Prostate Cancer

Can dose intensification improve outcomes for intermediate- or high-risk prostate cancer?

Yes, early evidence suggests dose intensification to visible tumors may improve outcomes for intermediate- or high-risk prostate cancer, but ongoing trials will clarify safety and efficacy.

Full answer →
Is there more research on macrophage polarization for prostate cancer since 2015?

Yes, research on macrophage polarization in prostate cancer has grown significantly since 2015, with studies exploring its role in tumor progression and therapy resistance.

Full answer →
Can enzalutamide plus ADT improve survival for metastatic hormone-sensitive prostate cancer?

Yes, enzalutamide plus ADT significantly improves survival in metastatic hormone-sensitive prostate cancer, with a 34% reduction in risk of death and a 5-year survival rate of 66% versus 53% with ADT alone.

Full answer →